Prosecution Insights
Last updated: November 20, 2026
Application No. 18/506,379

NKG2D-IG FUSION PROTEIN FOR CANCER IMMUNOTHERAPY

Non-Final OA §102§DOUBLEPATENT
Filed
Nov 10, 2023
Priority
Nov 13, 2015 — provisional 62/255,016 +3 more
Examiner
XIAO, YAN
Art Unit
1642
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Dana-Farber Cancer Institute Inc.
OA Round
1 (Non-Final)
68%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 68% — above average
68%
Career Allowance Rate
521 granted / 772 resolved
+7.5% vs TC avg
Strong +53% interview lift
Without
With
+52.7%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
51 currently pending
Career history
810
Total Applications
across all art units

Statute-Specific Performance

§101
4.8%
-35.2% vs TC avg
§103
26.4%
-13.6% vs TC avg
§102
18.8%
-21.2% vs TC avg
§112
27.0%
-13.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 772 resolved cases

Office Action

§102 §DOUBLEPATENT
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION 2. The election without traverse filed 09/09/2026 in response to the Office Action of 07/15/2026 is acknowledged and has been entered. Applicant has elected Group I, claims 30-38, drawn to a polypeptide chain comprising: (a) a first ligand binding fragment of human NKG2D; (b) a second ligand binding fragment of human NKG2D; and (c) an Fc domain of a human immunoglobulin comprising: (i) a CH2 domain; and (ii) a CH3 domain. 3. Claims 30-49 are pending in the application. Claims 39-49 have been withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to nonelected inventions, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 09/09/2026. 4. Claims 30-38 are currently under prosecution. Priority 5. Applicant’s claim under 35 U.S.C. §§ 119(e), 121 and 365(c) for benefit of the earlier filing date of applications, is acknowledged. 6. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Claim Rejections - 35 USC § 102 7. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention. 8. Claims 30-38 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Dranoff et al. (US 20110311535, December 22, 2011, IDS). Claims 30-38 are herein drawn to a polypeptide chain comprising: (a) a first ligand binding fragment of human NKG2D; (b) a second ligand binding fragment of human NKG2D; and (c) an Fc domain of a human immunoglobulin comprising: (i) a CH2 domain; and (ii) a CH3 domain. Dranoff et al. teach a composition comprising a NKG2D-Fc chimera and a pharmaceutically acceptable carrier, wherein the NKG2D-Fc chimera binds to one or more NKG2D ligands; see entire document, e.g. claims 1-11, abstract, [0007-0012], Fig. 1. Dranoff et al. teach that a recombinant NKG2D-Fc molecule can form a dimer by virtue of the hinge region of the Fc fragment that mediates dimer formation by disulfide bonding (see [0035], [0078]), which would be the same as the instant invention of Fig. 1. For claim 31, Dranoff et al. teach that the NKG2D-Fc chimera comprises an NKG2D extracellular domain; see [0010], claim 5. For claim 34, Dranoff et al. teach the ligand-binding domain of human NKG2D coupled to the Fc region of human IgG1; see [0030]. For claims 35-37, Dranoff et al. teach that the NKG2D-Fc chimera comprises a linking molecule, wherein the linker is a flexible peptide linker, wherein the linker comprises two or more of the following amino acids: glycine, serine, alanine, and threonine; see claims 2-4, [0066-0067]. Double Patenting 9. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the claims at issue are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the reference application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The USPTO internet Web site contains terminal disclaimer forms which may be used. Please visit http://www.uspto.gov/forms/. The filing date of the application will determine what form should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to http://www.uspto.gov/patents/process/file/efs/guidance/eTD-info-I.jsp. 10. Claims 30-38 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-14 of U.S. Patent No. 10,865,232. Although the conflicting claims are not identical, they are not patentably distinct from each other because for the following reasons: Claims 30-38 are herein drawn to a polypeptide chain comprising: (a) a first ligand binding fragment of human NKG2D; (b) a second ligand binding fragment of human NKG2D; and (c) an Fc domain of a human immunoglobulin comprising: (i) a CH2 domain; and (ii) a CH3 domain. Claims 1-14 of U.S. Patent No. 10,865,232 are drawn to a dimeric NKG2D-Fc chimera including two distinct NKG2D ligand binding sites, each NKG2D ligand binding site attached to an Fc fragment, wherein: each NKG2D ligand binding site comprises NKG2D or a ligand binding portion of NKG2D; and the Fc fragment comprises a fragment crystallizable region (Fc) of an immunoglobulin. Conclusion 11. No claim is allowed. 12. Any inquiry concerning this communication or earlier communications from the examiner should be directed to YAN XIAO whose telephone number is (571)270-3578. The examiner can normally be reached M-F 8-5 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Samira Jean-Louis can be reached on 571-270-3503. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /YAN XIAO/Primary Examiner, Art Unit 1642
Read full office action

Prosecution Timeline

Nov 10, 2023
Application Filed
Oct 29, 2026
Non-Final Rejection mailed — §102, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12797483
PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, CONTAINING LIPID-PHOTOTHERMAL NANOPARTICLE HAVING ANTIBODY BOUND TO SURFACE
3y 7m to grant Granted Nov 17, 2026
Patent 12797481
DEVELOPMENT OF DRUG THERAPEUTIC AGENT CONTAINING ADAPTOR AND USE THEREOF
3y 8m to grant Granted Nov 17, 2026
Patent 12780920
NOVEL AGENTS AND USES THEREOF
4y 5m to grant Granted Nov 03, 2026
Patent 12780934
ANTIBODIES TO CANCER GLYCOSYLATION AND USES THEREOF
3y 3m to grant Granted Nov 03, 2026
Patent 12773405
COMBINATION OF LURBINECTEDIN AND IMMUNE CHECKPOINT INHIBITORS
1y 6m to grant Granted Oct 27, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
68%
Grant Probability
99%
With Interview (+52.7%)
2y 11m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 772 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month